Drugs / Shenbai Granules
Shenbai Granules
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03616444 | Dec 2018 → Jun 2023 | — | Jiangsu Famous Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07123116 | Aug 2025 → Nov 2028 expected | colorectal adenoma | Jiangsu Famous Medical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT07129499 | Aug 2025 → Nov 2028 expected | colorectal adenoma | Jiangsu Famous Medical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shenbai Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03616444 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Based on TCM,previous studies have found that Shenbai Granules can significantly reduce the recurrence and deterioration rate of colorectal adenomatous polyps” NCT03616444 ↗ |
| Route | Oral | “Orally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day.” NCT03616444 ↗ |